Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Zevra Therapeutics (ZVRA) Long-Term Debt Issuances (2022 - 2024)

Zevra Therapeutics (ZVRA) has disclosed Long-Term Debt Issuances for 3 consecutive years, with $59.0 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Long-Term Debt Issuances rose 51845.61% year-over-year to $59.0 million, compared with a TTM value of $59.0 million through Sep 2025, down 5.8%, and an annual FY2024 reading of $59.0 million, up 39.03% over the prior year.
  • Long-Term Debt Issuances was $59.0 million for Q2 2024 at Zevra Therapeutics, up from $3.6 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $59.0 million in Q2 2024 and bottomed at -$114000.0 in Q2 2023.
  • Average Long-Term Debt Issuances over 3 years is $19.0 million, with a median of $12.9 million recorded in 2022.
  • The sharpest move saw Long-Term Debt Issuances crashed 100.89% in 2023, then soared 51845.61% in 2024.
  • Year by year, Long-Term Debt Issuances stood at $12.8 million in 2022, then tumbled by 71.64% to $3.6 million in 2023, then surged by 1525.07% to $59.0 million in 2024.
  • Business Quant data shows Long-Term Debt Issuances for ZVRA at $59.0 million in Q2 2024, $3.6 million in Q4 2023, and $26.0 million in Q3 2023.